After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a ...

Agappe Corporate Office COCHIN, KERALA, INDIA, June 20, 2025 /EINPresswire / -- Agappe Diagnostics Ltd is poised to pioneer a transformative c ...

Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by ...

It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co ...

In May, the U.S. Food and Drug Administration (FDA) cleared the first-ever blood test to detect Alzheimer’s, announcing its ...

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

TAMPA, Fla. — It is a big step forward in Alzheimer’s research as the FDA approves the first blood test to help aid the diagnosis of Alzheimer's Disease. The Lumipulse test (Lumipulse G ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, exhibiting ...

Alzheimer's blood test, amyloid plaques, brain health screening, cognitive decline, dementia testing, digital, Early Detection, FDA approval, Lumipulse G test, medical breakthrough, neurological ...